Differential requirements for Ras and the retinoblastoma tumor suppressor protein in the androgen dependence of prostatic adenocarcinoma cells

Cell Growth and Differentiation

Volumn 11, Issue 7, 2000, Pages 361-372

  Fribourg, Anne F ^a   Knudsen, Karen E ^a   Strobeck, Matthew W ^a   Lindhorst, Clint M ^a   Knudsen, Erik S ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CYCLIN DEPENDENT KINASE; CYCLINE; RAS PROTEIN; RETINOBLASTOMA PROTEIN;

ARTICLE; CELL CYCLE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ANDROGENS; ANIMALS; BROMODEOXYURIDINE; CDC2-CDC28 KINASES; CELL CYCLE; CELL LINE; CULTURE MEDIA; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASES; CYCLINS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FIBROBLASTS; GENETIC VECTORS; HUMANS; IMMUNOBLOTTING; MALE; NEOPLASMS, HORMONE-DEPENDENT; PHOSPHORYLATION; PLASMIDS; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RATS; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033865682     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Roussel, M. F. Key effectors of signal transduction and G1 progression. Adv. Cancer Res., 74: 1-24, 1998.
2. Sherr, C. J. Cancer cell cycles. Science (Washington DC), 274: 1672-1677, 1996.
3. Denmeade, S. R., Lin, X. S., and Isaacs, J. T. Role of programmed apoptotic cell death during the progression and therapy for prostate cancer. Prostate, 28: 251-265, 1996.
4. Isaacs, J. T., Antagonistic effect of androgen on prostatic cell death. Prostate, 5: 545-557, 1984.
5. Montie, J. E., and Pienta, K. J. Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology, 43: 892-899, 1994.
6. Lara, P. N., and Meyers, F. J. Treatment options in androgen-independent prostate cancer. Cancer Investig., 17: 137-144, 1999.
7. Wilding, G., Endocrine control of prostate cancer. Cancer Surv., 23: 43-62, 1995.
8. Schroder, F. H., Endocrine therapy: where do we stand and where are we going? Cancer Surv., 11: 177-194, 1991.
9. Cunha, G. R., Donjacour, A. A., Cooke, P. S., Mee, S., Bigsby, R. M., Higgins, S. J., and Sugimura, Y. The endocrinology and developmental biology of the prostate. Endocr. Rev., 8: 338-362, 1987.
10. Trapman, J., and Cleutjens, K. B. J. M. Androgen-regulated gene expression in prostate cancer. Semin. Cancer Biol., 8: 29-36, 1997.
11. Cheng, M., Sexl, V., Sherr, C. J., and Roussel, M. F. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc. Natl. Acad. Sci. USA, 95: 1091-1096, 1998.
12. Sherr, C. J., Kato, J., Quelle, D. E., Matsuoka, M., and Roussel, M. F. D-type cyclins and their cyclin-dependent kinases: G1 phase integrators of the mitogenic response. Cold Spring Harbor Symp. Quant. Biol., 59: 11-19, 1994.
13. Weinberg, R. A., The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
14. Knudsen, E. S., and Wang, J. Y. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J. Biol. Chem., 271: 8313-8320, 1996.
15. Knudsen, E. S., and Wang, J. Y. J. Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase mediated RB phosphorylation. Mol. Cell. Biol., 17: 5771-5783, 1997.
16. Knudsen, E. S., Buckmaster, C., Chen, T. T., Feramisco, J. R., and Wang, J. Y. Inhibition of DNA synthesis by RB: effects on G1/S transition and S-phase progression. Genes Dev., 12: 2278-2292, 1998.
17. Knudsen, K. E., Weber, E., Arden, K. C., Cavenee, W. K., Feramisco, J. R., and Knudsen, E. S. The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death. Oncogene, 18: 5239-5245, 1999.
18. Knudsen, K. E., Fribourg, A. F., Strobeck, M. W., Blanchard, J-M., and Knudsen, E. S. Cyclin A is a functional target of retinoblastoma tumor suppressor protein (RB)-mediated cell cycle arrest. J. Biol. Chem., 274: 27632-27641, 1999.
19. Phillips, A., Huet, X., Plet, A., Le Cam, L., Viae, A., and Blanchard, J. M. The retinoblastoma protein is essential for cyclin A repression in quiescent cells. Oncogene, 16: 1373-1381, 1998.
20. Alevizopoulos, K., Vlach, J., Hennecke, S., and Amati, B. Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins. EMBO J., 16: p. 5322-5333, 1997.
21. Sherr, C. J., Mammalian G1 cyclins and cell cycle progression. Proc. Assoc. Am. Physicians, 107: 181-186, 1995.
22. Pagano, M., Pepperkok, R., Verde, F., Ansorge, W., and Draetta, G. Cyclin A is required at two points in the human cell cycle. EMBO J., 11: 961-971, 1992.
23. Horoszewicz, J. S., Leong, S. S., Chu, T. M., Wajsman, Z. L., Friedman, M., Papsidero, L., Kim, U., Chai, L. S., Kakati, S., Arya, S. K., and Sandberg, A. A. The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog. Clin. Biol. Res., 37: 115-132, 1980.
24. Jenster, G. The role of the androgen receptor in the development and progression of prostate cancer. Semin. Oncol., 26: 407-421, 1999.
25. Knudsen, K. E., Arden, K. C., and Cavenee, W. K. Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J. Biol. Chem., 273: 20213-20222, 1998.
26. Roussel, M. F., Theodoras, A. M., Pagano, M., and Sherr, C. J. Rescue of defective mitogenic signaling by D-type cyclins. Proc. Natl. Acad. Sci. USA, 92: 6837-6841, 1995.
27. Denhardt, D. T. Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling. Biochem. J., 378: 729-747, 1996.
28. Lin, A. W., Barradas, M., Stone, J. C., van Aelst, L., Serrano, M., and Lowe, S. W. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signalling. Genes Dev., 12: 3008-3019, 1998.
29. Campbell, S. L., Khosravi-Far, R., Rossman, K., Clark, G. J., and Der, C. J. Increasing complexity of Ras signaling. Oncogene, 17: 1395-1413, 1998.
30. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., and Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p16ink4a and p53. Cell, 88: 593-602, 1997.
31. Arap, W., Knudsen, E., Sewell, D. A., Sidransky, D., Wang, J. Y., Huang, H. J., and Cavenee, W. K. Functional analysis of wild-type and malignant glioma derived CDKN2Aβ alleles: evidence for an RB-independent growth suppressive pathway. Oncogene, 15: 2013-2020, 1997.
32. Arap, W., Knudsen, E. S., Wang, J. Y., Cavenee, W. K., and Huang, H. J. Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma. Oncogene, 14: 603-609, 1997.
33. Sherr, C. J., and Roberts, J. M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev., 13: 1501-1512, 1999.
34. Mittnacht, S., Paterson, H., Olson, M. F., and Marshall, C. J. Ras signalling is required for inactivation of the tumour suppressor pRb cell-cycle control protein. Curr. Biol., 7: 219-221, 1997.
35. Kang, J. S., and Krauss, R. S. Ras induces anchorage-independent growth by subverting multiple adhesion-regulated cell cycle events. Mol. Cell. Biol., 16: 3370-3380, 1996.
36. Sewing, A., Wiseman, B., Lloyd, A. C., and Land, H. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol. Cell. Biol., 17: 5588-5597, 1997.
37. Pergolizzi, R. G., Kreis, W., Rottach, C., Susin, M., and Broome, J. D. Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cells lines derived from primary and metastatic prostate carcinomas. Cancer Investig., 11: 25-32, 1993.
38. Capella, G., Cronauer-Mitra, S., Pienado, M. A., and Perucho, M. Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Environ. Health Perspect., 93: 125-131, 1991.
39. Carter, B. S., Epstein, J. I., and Isaacs, W. B. ras gene mutations in human prostate cancer. Cancer Res., 50: 6830-6832, 1990.
40. Gumerlock, P. H., Poonamallee, U. R., Meyers, F. J., and deVere White, R. W. Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res., 51: 1632-1637, 1991.
41. Moul, J. W., Friedrichs, P. A., Lance, R. S., Theune, S. M., and Chang, E. H. Infrequent RAS oncogene mutations in human prostate cancer. Prostate, 20: 327-338, 1992.
42. Phillips, S. M., Barton, C. M., Lee, S. J., Morton, D. G., Wallace, D. M., Lemoine, N. R., and Neoptolemos, J. P. Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostate tumorigenesis. Br. J. Cancer, 70: 1252-1257, 1994.
43. Mack, P. C., Chi, S. G., Meyers, F. J., Stewart, S. L., de Vere White, R. W., and Gumerlock, P. H. Increased RB1 abnormalities in human primary prostate cancer following combined androgen blockade. Prostate, 34: 145-151, 1998.
44. Lee, C. T., Capodieci, P., Osman, I., Fazzari, M., Ferrara, J., Scher, H. I., and Cordon-Cardo, C. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin. Cancer Res., 5: 977-983, 1999.
45. Voeller, H. J., Wilding, G., and Gelmann, E. P. v-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells. Mol. Endocrinol., 5: 209-216, 1991.
46. Ravi, R. K., McMahon, M., Yangang, Z., Williams, J. R., Dillehay, L. E., Nelkin, B. D., and Mabry, M. Raf-1 induced cell cycle arrest in LNCaP human prostate cancer cells. J. Cell. Biochem., 72: 458-469, 1999.
47. Brugarolas, J., Moberg, K., Boyd, S. D., Taya, Y., Jacks, T., and Lees, J. A. Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proc. Natl. Acad. Sci. USA, 96: 1002-1007, 1999.
48. Lundberg, A. S., and Weinberg, R. A. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol. Cell. Biol., 18: 753-761, 1998.
49. Jarrard, D. F., Kinoshita, H., Shi, Y., Sandefur, C., Hoff, D., Meisner, L. F., Chang, C., Herman, J. G., Isaacs, W. B., and Massif, N. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res., 58: 5310-5314, 1998.
50. Muraki, J., Addonizio, J. C., Choudhury, M. S. Fischer, J., Eshghi, M., Davidian, M. M., Shapiro, L., R., Wilmot, P. L., Nagamatsu, G. R., and Chiao J. W. Establishment of new human prostatic cancer cell line (JCA-1). Urology, 36: 79-84, 1990.
51. Tetsu, O., and McCormick, F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature (Lond.), 398: 422-426, 1999.
52. Chen, C., and Okayama, H. High efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol., 7: 2745-2752, 1987.
53. Knudsen, E. S., Pazzagli, C., Born, T. L., Bertolaet, B., Knudsen, K. E., Arden, K. C., Henry, R. R., and Feramisco, J. R. Elevated cyclins and cyclin-dependent kinase activity in the rhabdomyosarcoma cell line RD. Cancer Res., 58: 2042-2049, 1998.
54. LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., and Harlow, E. New functional activities for the p21 family of CDK inhibitors. Genes Dev., 11: 847-862, 1997.